Mechanistic analysis showed that AML1-ETO or PML-RARα fusion oncogenes can inhibit HR activity through suppressing several HR-associated genes in AML cells, thus leading to olaparib sensitivity (Figure 2) (Esposito et al., 2015). The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.